Tagged with generics,

generics Carlos Leigh, executive president of Peru’s Asociación de Laboratorios Farmacéuticos Latinoamericanos (ALAFAL), discusses the advantages that LATAM companies have over big pharma players looking to enter the Peruvian market, and offers his predictions for the future of the sector for growth. Can you introduce yourself to our readers? I actively worked in…

heparin The vice president of Laboratorio Tuteur highlights the position of his company as the leaders in specialty products in Argentina.   Could you please give us an historical overview of Laboratorio Tuteur S.A.C.I.F.I.A., a company with more than 40 years of history? Laboratorio Tuteur S.A.C.I.F.I.A. is a company based in Argentina…

generics  Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth in the future.   You are currently the Vice President of CAPGEN; could you please tell us a bit about…

development Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations.    How did you become part of Glenmark, and what was your main objective when you took the helm in Argentina? I joined Glenmark five years ago as…

family business President of the company, Alberto Alvarez-Saavedra, discusses the company’s transformation into a professional organization, and the strategy which has driven remarkable growth in recent years, and will continue to do so as they expand across the region. What have been your main achievements since you took over as the President of…

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

similars The vice president of Laboratorios Beta discusses the factors of why his organization is on the  way to consolidating its different business lines and becoming a pure pharmaceutical company.     2014 marks the 74th anniversary of Laboratorios Beta. To what extent is the company today still the same company…

generics Chile is aiming to achieve complete bioequivalence of generics by the end of 2014. Chile’s Public Health Institute is leading the bioequivalence testing, aimed at regulating differences between generic and bioequivalent drugs. The recently appointed director of the Public Health Institute, Ricardo Fabrega, echoes the need for drastic change and…

Indian When Indian generics company Aurobindo established itself in Portugal in 2010, the affiliate was faced with some difficult choices. As the latest company to enter the Portuguese generic market, Aurobindo had the lowest prices in the market, which was not attractive to the pharmacy channel. Pedro Merlini, country manager of…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…